Thank you to all who attended the first TIDES Virtual conference. Over 1300 attendees participated during the week which featured over 160 on-demand speaker presentations and 20+ live panel discussions and other sessions. We want to thank you for your understanding and support as we navigated various technical issues during the week.
The most common piece of positive feedback we received following the event is that attendees really enjoyed the live Q&A and live speaker panel discussions which allowed attendees to interact with speakers/panelists by asking questions using either the chat pod, or live using their camera/microphone.
Many attendees also let us know they really enjoyed the opportunity to re-watch on-demand presentations multiple times, as well as the fact that these on-demand presentations will be available for viewing for 30 days post-event.
As the leading industry event covering oligonucleotides, peptides, mRNA, genome editing and delivery of macromolecules, the TIDES event team was very happy to be able to deliver this exciting content to you virtually and we hope to see you again soon at the next event in the TIDES series, TIDES Europe, taking place November 11-13, 2021.
Stay safe and well,
1. Key Themes of The Event - Executive Summary
Biotech researcher and writer Dr. Catarina Carrao reflects on the main themes of the event, explored through top keynotes and panel sessions, in this executive summary.
2. Top Keynote Presentation: Tuning siRNA Potency, Specificity and Distribution through Chemistry
Prof. Anastasia Khvorova, Professor at University of Massachusetts Medical School detailed the methods of optimizing siRNAs within the chemistry process in a keynote session and Q&A.
3. Hot Topic Keynote Presentation: mRNA as Medicine
In an exciting keynote, Dr. Melissa Moore, Chief Scientific Officer, Moderna Therapeutics, Inc. revealed the latest uses of messenger RNA in drug and vaccine development.
4. Poster: A Universal Method for the Quantitation of Multiple Oligonucleotides from Plasma by MFLC-MS/MS
This popular poster and presentation by Chad Christianson, Senior Principal Scientist at Alturas Analytics, describes a method of bioanalysis of oligonucleotides which shows numerous benefits over ELISA and qPCR.
5. On-demand Session: Oligonucleotide Manufacturing Capabilities at Ajinomoto Bio-Pharma Services
Soichi Utsumi, General Manager of Sales at Aji Bio-Pharma Osaka, introduced the leading oligo capabilities and novel technologies at Ajinomoto Bio-Pharma.
6. On-demand Session: An Approach to Process Validation for Peptides: Applying Bachem CMC concept to (Nle3)-Angiotensin I/II validation, a case study
Matteo Villain, Ph.D., Vice President, CMC Development at Bachem Americas, Inc. describes the company's approach to Process Design and Process Qualification of peptidic API as demonstrated in a case study for (Nle3)-Angiotensin I/II validation.
